Co-inhibition of IGF-1/PI3K and CSF-1R using OSI906/Linsitinib +BLZ945 was found to overcome tumor resistance to BLZ945 therapy, and extend median survival of mice from 13 days to 63 days22. Here, PIK3CG is linked to neoplasm.